Publication Date
| In 2025 | 0 |
| Since 2024 | 0 |
| Since 2021 (last 5 years) | 0 |
| Since 2016 (last 10 years) | 0 |
| Since 2006 (last 20 years) | 2 |
Descriptor
| Adolescents | 2 |
| Children | 2 |
| Depression (Psychology) | 2 |
| Drug Therapy | 2 |
| Pain | 2 |
| Pediatrics | 2 |
| Suicide | 2 |
| Symptoms (Individual… | 2 |
| Age Differences | 1 |
| Body Weight | 1 |
| Comparative Analysis | 1 |
| More ▼ | |
Author
| Findling, Robert L. | 2 |
| Emslie, Graham J. | 1 |
| Jonas, Jeffrey | 1 |
| Kunz, Nadia R. | 1 |
| Li, Yunfeng | 1 |
| Saikali, Khalil | 1 |
| Ventura, Daniel | 1 |
| Wagner, Karen Dineen | 1 |
| Yeung, Paul P. | 1 |
Publication Type
| Journal Articles | 2 |
| Reports - Research | 2 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Peer reviewed
Direct linkEmslie, Graham J.; Findling, Robert L.; Yeung, Paul P.; Kunz, Nadia R.; Li, Yunfeng – Journal of the American Academy of Child & Adolescent Psychiatry, 2007
Objective: The safety, efficacy, and tolerability of venlafaxine extended release (ER) in subjects ages 7 to 17 years with major depressive disorder were evaluated in two multicenter, randomized, double-blind, placebo-controlled trials conducted between October 1997 and August 2001. Method: Participants received venlafaxine ER (flexible dose,…
Descriptors: Safety, Patients, Adolescents, Suicide
Wagner, Karen Dineen; Jonas, Jeffrey; Findling, Robert L.; Ventura, Daniel; Saikali, Khalil – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Objective: Escitalopram is a selective serotonin reuptake inhibitor antidepressant indicated for use in adults. This trial examined the efficacy and safety of escitalopram in pediatric depression. Method: Patients (6-17 years old) with major depressive disorder were randomized to receive 8 weeks of double-blind flexibly dosed treatment with…
Descriptors: Pediatrics, Least Squares Statistics, Depression (Psychology), Drug Therapy
